| 產品編號 | bs-12849R-Gold |
| 英文名稱 | Rabbit Anti-phospho-Survivin (Thr34)/Gold Conjugated antibody |
| 中文名稱 | 膠體金標記的磷酸化細胞凋亡抑制因子抗體 |
| 別 名 | Survivin (phospho T34); p-Survivin (phospho T34); API4; Apoptosis Inhibitor 4; Apoptosis inhibitor survivin; Apoptosis inhibitor4; Baculoviral IAP repeat containing 5; Baculoviral IAP repeat containing 5; Baculoviral IAP repeat containing protein 5; Baculoviral IAP repeat-containing protein 5; BIRC 5; BIRC 5; BIRC5; BIRC5_HUMAN; EPR 1; EPR 1; IAP4; IAP4; Survivin variant 3 alpha; SVV; SVV; TIAP; TIAP. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 產品類型 | 磷酸化抗體 |
| 研究領域 | 腫瘤 細胞生物 神經生物學 細胞凋亡 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, ) |
| 產品應用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 16kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human Survivin around the phosphorylation site of Thr34 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產品介紹 |
background: This gene is a member of the inhibitor of apoptosis (IAP) gene family, which encode negative regulatory proteins that prevent apoptotic cell death. IAP family members usually contain multiple baculovirus IAP repeat (BIR) domains, but this gene encodes proteins with only a single BIR domain. The encoded proteins also lack a C-terminus RING finger domain. Gene expression is high during fetal development and in most tumors, yet low in adult tissues. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, Jun 2011] Function: Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May play a role in neoplasia. May counteract a default induction of apoptosis in G2/M phase. Inhibitor of caspase-3 and caspase-7. Isoform 2 and isoform 3 do not appear to play vital roles in mitosis. Isoform 3 shows a marked reduction in its anti-apoptotic effects when compared with the displayed wild-type isoform. Subcellular Location: Cytoplasm. Nucleus. Chromosome. Chromosome > centromere. Cytoplasm > cytoskeleton > spindle. Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis. Colocalizes with AURKB at mitotic chromosomes. Tissue Specificity: Expressed only in fetal kidney and liver, and to lesser extent, lung and brain. Abundantly expressed in adenocarcinoma (lung, pancreas, colon, breast, and prostate) and in high-grade lymphomas. Also expressed in various renal cell carcinoma cell lines. Post-translational modifications: Ubiquitination is required for centrosomal targeting. In vitro phosphorylation at Thr-117 by AURKB/STK12 prevents interaction with INCENP and localization to mitotic chromosomes. Similarity: Belongs to the IAP family. Contains 1 BIR repeat. Database links: Entrez Gene: 332 Human Entrez Gene: 11799 Mouse Omim: 603352 Human SwissProt: O15392 Human SwissProt: O70201 Mouse Unigene: 514527 Human Unigene: 8552 Mouse Unigene: 54471 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
